Development and Validation of the Patient/Caregiver Reported Hydroxyurea Evaluation of Adherence for Life (HEAL) Scale

Overview

Journal Patient Prefer Adherence

Date 2022 Dec 19

PMID 36531301

Authors

Isaac A Janson

Ellen M Bloom

Kisha C Hampton

Emily Riehm Meier

Angeli G Rampersad

William G Kronenberger

Affiliations

Soon will be listed here.

Abstract

Introduction: Hydroxyurea reduces the incidence of vaso-occlusive episodes, stroke, and respiratory, cardiac, and renal damage in sickle cell disease by increasing fetal hemoglobin. However, because suboptimal adherence to hydroxyurea limits its effectiveness, understanding patient-specific barriers to hydroxyurea adherence could help improve adherence and health outcomes in patients with sickle cell disease. The aim of this single-site, prospective, IRB-approved study was to validate a 24-item patient- and caregiver-reported hydroxyurea treatment adherence questionnaire, the Hydroxyurea Evaluation of Adherence for Life (HEAL) scale.

Methods: A sample of 24 adults with sickle cell disease and 16 caregivers of children with sickle cell disease completed the HEAL scale, and a subset of the original sample provided a second HEAL scale for test-retest reliability. HEAL scale results were validated against global adherence ratings from participants and health-care providers, records of access to pill bottles, and laboratory values for fetal hemoglobin and absolute neutrophil count.

Results And Discussion: Results demonstrated excellent internal consistency for the HEAL Total score and eight (3-item) subscale scores (Dose, Remember, Plan, Cost, Understand, Effectiveness, Laboratory, and Pharmacy), as well as strong test-retest reliability for all HEAL scores except the Cost subscale. HEAL Total scores correlated significantly with validity measures, including global adherence ratings and lab values. The HEAL scale offers significant clinical potential for understanding adherence in individual sickle cell disease patients and significant research potential for characterizing adherence in persons with sickle cell disease who are treated with hydroxyurea.

References

Duncan N, Kronenberger W, Roberson C, Janson I, Shapiro A . Adherence is a human behaviour, assessing it requires multimethod evaluation with validated measures: Comment on Guedes VG et al (2019). Haemophilia. 2020; 26(6):934-936. DOI: 10.1111/hae.14022. View

Meier E, Rampersad A . Pediatric sickle cell disease: past successes and future challenges. Pediatr Res. 2016; 81(1-2):249-258. DOI: 10.1038/pr.2016.204. View

Duncan N, Kronenberger W, Roberson C, Shapiro A . VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia. 2009; 16(2):247-55. DOI: 10.1111/j.1365-2516.2009.02129.x. View

Okocha E, Gyamfi J, Ryan N, Babalola O, Etuk E, Chianumba R . Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey. Front Genet. 2022; 12:765958. PMC: 8807646. DOI: 10.3389/fgene.2021.765958. View

Haywood Jr C, Beach M, Bediako S, Carroll C, Lattimer L, Jarrett D . Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2010; 86(1):85-7. PMC: 3233349. DOI: 10.1002/ajh.21883. View

Piccin A, Murphy C, Eakins E, Kunde J, Corvetta D, Di Pierro A . Circulating microparticles, protein C, free protein S and endothelial vascular markers in children with sickle cell anaemia. J Extracell Vesicles. 2015; 4:28414. PMC: 4658688. DOI: 10.3402/jev.v4.28414. View

Candrilli S, OBrien S, Ware R, Nahata M, Seiber E, Balkrishnan R . Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011; 86(3):273-7. DOI: 10.1002/ajh.21968. View

Fogarty H, Gaul A, Syed S, Aleksejenko N, Geoghegan R, Conroy H . Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease. Ir J Med Sci. 2021; 191(2):809-816. PMC: 8983545. DOI: 10.1007/s11845-021-02588-1. View

Steinberg M, Lu Z, Barton F, Terrin M, CHARACHE S, Dover G . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997; 89(3):1078-88. View

10.

Creary S, Chisolm D, Stanek J, Hankins J, OBrien S . A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. JMIR Mhealth Uhealth. 2019; 7(8):e13452. PMC: 6705009. DOI: 10.2196/13452. View

11.

Lam W, Fresco P . Medication Adherence Measures: An Overview. Biomed Res Int. 2015; 2015:217047. PMC: 4619779. DOI: 10.1155/2015/217047. View

12.

Lanzkron S, Haywood Jr C, Segal J, Dover G . Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006; 81(12):927-32. DOI: 10.1002/ajh.20703. View

13.

Nottage K, Hankins J, Smeltzer M, Mzayek F, Wang W, Aygun B . Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PLoS One. 2013; 8(8):e72077. PMC: 3743768. DOI: 10.1371/journal.pone.0072077. View

14.

Hassell K . Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010; 38(4 Suppl):S512-21. DOI: 10.1016/j.amepre.2009.12.022. View

15.

Patel N, Lindsey T, Strunk R, DeBaun M . Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis. Pediatr Blood Cancer. 2010; 55(3):554-6. PMC: 3665080. DOI: 10.1002/pbc.22605. View

16.

Duncan N, Kronenberger W, Hampton K, Bloom E, Rampersad A, Roberson C . A validated measure of adherence to antibiotic prophylaxis in children with sickle cell disease. Patient Prefer Adherence. 2016; 10:983-92. PMC: 4908942. DOI: 10.2147/PPA.S103874. View

17.

Olivieri N, Vichinsky E . Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998; 20(1):26-31. DOI: 10.1097/00043426-199801000-00004. View

18.

. From the Centers for Disease Control and Prevention. Mortality among children with sickle cell disease identified by newborn screening during 1990-1994--California, Illinois, and New York. JAMA. 1998; 279(14):1059-60. View

19.

Brandow A, Jirovec D, Panepinto J . Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010; 85(8):611-3. PMC: 2911651. DOI: 10.1002/ajh.21749. View

20.

Orringer E, Blythe D, Johnson A, Phillips Jr G, Dover G, Parker J . Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood. 1991; 78(1):212-6. View